Orgenesis and ERYTECH Pharma Partner With The New York Blood Center

Creative Commons License New York. Source: Walkerssk, no changes made.
Advertisement img

Orgenesis Inc., a developer, service provider and manufacturer of advanced cell therapies, has announced that it has entered into a collaboration agreement with the New York Blood Center (NYBC).

Under the agreement, NYBC will be responsible for establishing the infrastructure to collect, process, test, cryopreserve and biobank sampling materials, including liver biopsies. The samples are intended for use as source of autologous insulin producing (AIP) cells for patients that may be eligible for future clinical trials.

ERYTECH Pharma, a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating drug substances inside red blood cells, has also announced a strategic partnership with NYBC for red blood cell supply and research.

Featured Partners

Founded in 2008, headquartered in Germantown, Maryland, USA, Orgenesis is a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and support services. The company has a global contract development and manufacturing organization (CDMO) subsidiary, as well as developing its own cell therapy products for diabetes.

Founded in 2004, headquartered in Lyon, France, ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates to address markets with high unmet medical needs.

Founded in 1964, NYBC is a non-profit organization that is one of the largest independent, community-based blood centers in the world. NYBC, along with its partner organizations Community Blood Center of Kansas City, Missouri (CBC), Innovative Blood Resources (IBR), Blood Bank of Delmarva (BBD), and Rhode Island Blood Center (RIBC), collect approximately 4,000 units of blood products each day and serve local communities of more than 45 million people in the Tri-State area (NY, NJ, CT), Mid Atlantic area (PA, DE, MD), the Kansas City metropolitan area, Minnesota, Nebraska, Rhode Island, and Southern New England.

NYBC and its partners also provide a wide array of transfusion-related medical services, including Comprehensive Cell Solutions, the National Center for Blood Group Genomics, the National Cord Blood Program, and the Lindsley F. Kimball Research Institute, which, among other milestones, developed the Hepatitis B vaccine and a patented solvent detergent plasma process innovating blood-purification technology worldwide.

“This agreement marks an important milestone toward initiating our US clinical activities. We have utilized human biopsy samples in a wide range of animal trials, and this agreement will now enable us to collect the biopsies from patients for potential clinical use once we receive the appropriate regulatory approvals.” – Professor Sarah Ferber, Orgenesis Chief Scientific Officer

“We view the New York Blood Center (NYBC) as an ideal strategic partner for the expansion of our activity in the U.S. NYBC is well equipped to provide the necessary infrastructure to collect, process and biobank materials for both our diabetes program as well as for other development programs.  They have well established relationships with hundreds of hospitals in the U.S., which will be valuable during both the development and the commercial phases of our programs.  Moreover, this infrastructure provided by NYBC and their expert development team complements our cell collection and processing activities for research purposes in Belgium, Israel and South Korea, where we have set up similar programs.” – Vered Caplan, Chief Executive Officer of Orgenesis

“NYBC’s blood collection and processing scale in the Northeast United States will strengthen our RBC supply to be utilized at our New Jersey manufacturing site which is currently under construction,” … “We also look forward to working with NYBC to advance our preclinical platform based on our proprietary ERYCAPS® technology.” – Gil Beyen, Chief Executive Officer at ERYTECH

“We are delighted to partner with Orgenesis in advancing these disruptive cell therapies.  We look forward to leveraging both our infrastructure and hospital relationships to help accelerate the path to market and are looking forward to partnering on a broad range of projects.” – Beth Shaz, MD, Executive Vice President, of NYBC

“We are excited to partner with ERYTECH to advance the development of vital and novel cancer treatments,” … “Our state-of-the-art infrastructure and expertise in blood services and research make us uniquely suited to support clinical and preclinical activities with both products and laboratory services.” – Beth Shaz, MD, Executive Vice President, of NYBC